Altimmune Shares Dip Despite Positive Trial Results

Altimmune shares are trading lower after announcing positive topline results from its Phase 2b trial of pemvidutide, which met its primary endpoint with significant MASH resolution. Market reaction suggests concerns over statistical significance in fibrosis improvement.